JP2025505802A5 - - Google Patents
Info
- Publication number
- JP2025505802A5 JP2025505802A5 JP2024548635A JP2024548635A JP2025505802A5 JP 2025505802 A5 JP2025505802 A5 JP 2025505802A5 JP 2024548635 A JP2024548635 A JP 2024548635A JP 2024548635 A JP2024548635 A JP 2024548635A JP 2025505802 A5 JP2025505802 A5 JP 2025505802A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- oral dosage
- form according
- mass
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263311905P | 2022-02-18 | 2022-02-18 | |
| US63/311,905 | 2022-02-18 | ||
| US202263312650P | 2022-02-22 | 2022-02-22 | |
| US63/312,650 | 2022-02-22 | ||
| PCT/US2023/012935 WO2023158616A1 (en) | 2022-02-18 | 2023-02-13 | ORAL DOSAGE FORMS OF TRβ AGONIST VK2809 FOR THE TREATMENT OF LIVER DISORDERS AND METHODS OF PREPARING THE SAME |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025505802A JP2025505802A (ja) | 2025-02-28 |
| JP2025505802A5 true JP2025505802A5 (https=) | 2026-02-24 |
Family
ID=87578867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024548635A Pending JP2025505802A (ja) | 2022-02-18 | 2023-02-13 | 肝障害の処置のためのＴＲβアゴニストＶＫ２８０９の経口剤形及びそれを調製する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250134913A1 (https=) |
| EP (1) | EP4479062A4 (https=) |
| JP (1) | JP2025505802A (https=) |
| KR (1) | KR20240149941A (https=) |
| CN (1) | CN119072316A (https=) |
| AU (1) | AU2023220955A1 (https=) |
| CA (1) | CA3251549A1 (https=) |
| MX (1) | MX2024010009A (https=) |
| WO (1) | WO2023158616A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3053674T3 (en) | 2018-03-22 | 2026-01-23 | Viking Therapeutics Inc | Crystalline forms and methods of producing crystalline forms of a compound |
| WO2020117962A1 (en) | 2018-12-05 | 2020-06-11 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| CN118615254A (zh) * | 2023-03-08 | 2024-09-10 | 甘莱制药有限公司 | 片剂及其制备方法与用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL372247A1 (en) * | 2002-02-01 | 2005-07-11 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
| CL2004001884A1 (es) * | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros. |
| WO2007109605A2 (en) * | 2006-03-20 | 2007-09-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
| CN116942684A (zh) * | 2020-02-20 | 2023-10-27 | 甘莱制药有限公司 | 一种用于治疗脂肪性肝炎的药物组合物及其制备方法 |
| US11752161B2 (en) * | 2020-03-27 | 2023-09-12 | Gannex Pharma Co., Ltd. | Pharmaceutical compositions, method of making and method of using thereof |
| JP7470204B2 (ja) * | 2020-03-27 | 2024-04-17 | ガンネックス ファーマ カンパニー リミテッド | 医薬組成物、その調製方法及び使用方法 |
| TW202315608A (zh) * | 2021-07-06 | 2023-04-16 | 中國大陸商甘萊製藥有限公司 | 用於治療肝臟疾病的聯合治療 |
-
2023
- 2023-02-13 WO PCT/US2023/012935 patent/WO2023158616A1/en not_active Ceased
- 2023-02-13 AU AU2023220955A patent/AU2023220955A1/en active Pending
- 2023-02-13 JP JP2024548635A patent/JP2025505802A/ja active Pending
- 2023-02-13 US US18/836,719 patent/US20250134913A1/en active Pending
- 2023-02-13 CN CN202380034572.9A patent/CN119072316A/zh active Pending
- 2023-02-13 CA CA3251549A patent/CA3251549A1/en active Pending
- 2023-02-13 EP EP23756790.4A patent/EP4479062A4/en active Pending
- 2023-02-13 KR KR1020247030354A patent/KR20240149941A/ko active Pending
- 2023-02-13 MX MX2024010009A patent/MX2024010009A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025505802A5 (https=) | ||
| TWI649098B (zh) | （ｓ）-（１-（（４-（３-（５-氯-２-氟-３-（甲基磺醯胺基）苯基-１-異丙基-１ｈ-吡唑-４-基）嘧啶-２-基）胺基）丙-２-基)胺基甲酸甲酯之固體醫藥調配物 | |
| CN106943355B (zh) | 药物组合物 | |
| US11590127B2 (en) | Gastro-resistant formulation containing posaconazole | |
| JP2016188181A (ja) | ミラベグロン含有放出制御錠剤 | |
| JP6904955B2 (ja) | アプレミラスト徐放性製剤 | |
| EP2867199B1 (en) | Stable compositions of fesoterodine | |
| US9421165B2 (en) | Oral controlled release pharmaceutical compositions of bepotastine | |
| US11576917B2 (en) | Pharmaceutical compositions comprising Ibrutinib | |
| US20120035177A1 (en) | Tablet formulation for p38 inhibitor and method | |
| EP3925601B1 (en) | Gastro-resistant formulation containing posaconazole and a polymeric precipitation inhibitor | |
| US20090264460A1 (en) | Clopidogrel pharmaceutical formulations | |
| US20110217373A1 (en) | Extended release pharmaceutical compositions of guanfacine hydrochloride | |
| WO2022153330A1 (en) | Pharmaceutical compositions comprising acalabrutinib | |
| WO2022085015A1 (en) | A solid oral composition of teriflunomide | |
| US10010529B2 (en) | Extended release pharmaceutical formulations with controlled impurity levels | |
| RU2024120984A (ru) | Пероральные лекарственные формы для лечения расстройств печени и способы их получения | |
| US20240293399A1 (en) | Gastro-resistant high-strength formulation containing posaconazole | |
| WO2019064090A1 (en) | NOVEL PHARMACEUTICAL COMPOSITION COMPRISING MEFENAMIC ACID AND OTHER ANALGESICS | |
| WO2019132840A1 (en) | A pharmaceutical formulation for oral administration comprising dabigatran etexilate | |
| EA045272B1 (ru) | Твердая фармацевтическая композиция на основе гидрохлорида луразидона для перорального применения |